Kevin

Kevin from Alliance Global Partners inquired about the initial feedback received from trials of the newly launched Echoscope Type Nano Gen series and asked for an update on the DAVD-related revenue target, noting a reduction from $4.5 million to $3.5-$4 million since the March conference call.

Answer

Annmarie Gayle, Chair and CEO, and Blair Cunningham, President of Technology, explained that customers were highly impressed by the Nano Gen series' significant reduction in size and weight, which opens new integration opportunities, such as the DCEND diving suit. Regarding DAVD revenue, Ms. Gayle confirmed the company is targeting $4 million for the fiscal year, a substantial increase from $1.2 million in the previous year, expressing satisfaction with this progress.

Kevin asked about the feedback received from trials of the newly launched Echoscope Type Nano Gen series and sought clarification on the revised DAVD-related revenue target for the fiscal year.

Answer

Blair Cunningham, President of Technology, highlighted the significant reduction in the Nano Gen series' form factor, size, and weight as a key positive feedback, enabling new integration opportunities. Annmarie Gayle, Chair and CEO, confirmed the company is targeting $4 million in DAVD revenue for the fiscal year, a substantial increase from $1.2 million in the previous year, expressing satisfaction with the progress.